COMPOSITION OF PAPER

COMPOSITE OF NANOTUBES OR NANOFIBRES ON FOAM OF BETA-SIC

METHOD FOR PREPARING SUBSTITUTED AMINONITROBENZENES

COMPOSITION OF ADHESIVE COMPOSITION FOR SECONDARY TREATING OF FOAMPOLYURETANE

ADHESIVE COMPOSITION FOR STICKY BAND

COLLAPSIBLE PLASTIC WRAPPING

O- (METHYL- 5- NITROIMIDAZOL- 2- YL- METHYL)- N- TRICHLORACETYL CARBAMATE AND METHOD FOR ITS PREPARATION

MEANS FOR IMPAIRING BIOLOGICAL ACTIVITY TO FIBROUS MATERIAL

COMPOSITION FOR SIZING OF PAPERS FOR WRITING AND PRINTING

HYBRID MAIZE <KNEZHA 510>

COMPOSITION OF A COATING ON METALS

METHOD FOR SILVER EXTRACTION FROM PHOTOPAPER

MEANS FOR GROWTH REGULATION OF PLANTS

STAMP FOR DEFOPMING OF TUBE BLANKS

METHOD FOR PREPARING 1- METHYL- 2- HYDROXYMETHYL- 5- NITRO- 1H- IMIDAZOL

INSTRUMENT OF DETERMINATION THE DEGREE OF SHRINKING OF FILAMENT COVERING OF LEATHERS

A BINDING MATERIAL FOR CORE ALLOY FOR METAL-CASTING

METHOD FOR PREPARING SOLUBLE METAL- DESACTIVATING ADDITIVES

METHOD AND DEVICE FOR MODELLING PARAMETERS OF MOVING OBJECTS

METHOD FOR PREPARING SOLID OXIDIZED POLYETHYLENIC RESIN

METHOD FOR REFINING OF COPPER

PLASTIFIER

METHOD FOR IMMOBILIZING PENICILLINE- AMIDASE

MAIZE HYBRID <KNEJA MV- 293>

METHOD FOR PREPARING ALUMINIUM HYDROXY PHOSPHATE

MEANS FOR GROWTH REGULATION OF PLANTS

METHOD FOR OBTAINING OF METAL OXIDES

FIRE PROTECTIVE POLYMER COMPOSITION

APPARATUS FOR CUTTING UP ANIMALS HOOFS

METHOD FOR MANUFACTURING PROTEIN PREPARATION

DEVICE FOR ELIMINATING GASES FROM ELECTRIC ARC FURNACE

CONCETRATE FOR DRINKS

ELECTROLYTE FOR BRIGHT COPPER PLATING AND METHOD OF EFFECTING THE PROCESS

CATALYST FOR HYDROGENATING SUBSTITUTED NITROBENZENES AND METHOD FOR ITS PREPARATION

MEANS FOR BOILING OF WOOD

METHOD FOR MANUFACTURE OF COPPER- CHROME ALLOY

COMPOSITION OF KERAMIC MATERIAL WITH HIGH COEFFFICIENT OF DIFUSELY DIFRACTION

NITRATEREDUCTASE MEANS

APPARATUS FOR GATERING OF SUPPORTING DETAILS

METHOD FOR STYRENE POLYMERIZING

APPARATUS FOR DEPRESSION OF MINERAL COMPONENTS

BINDER FOR METAL CASTING AND METHOD FOR ITS MANUFACTURE

(+)- 4- PHENYL- 2- METHYL- 8- AMINO- 1, 2, 3, 4- TETRAHYDROISOQUINOLINE AND METHOD FOR ITS PREPARATION

METHOD FOR RAPE METALS

METHOD OF OBTAINING CONCENTRATED RUBBER LATEX

METHOD FOR IDENTIFICATION OF ANTIBODIES AGAINST L-FORMS OF BACTERIA

ADDITIVE FOR PORTLAND CEMENT CLINKER

MEANS FOR GROWTS REGULATION OF PLANTS

HEAD FOR LOCAL ELECTRIC SPARCLE LAYING OF METALS AND ALLOYS

METHOD FOR PREPARING DIMETHYL ESTER OF CYANIMIDODITHIOCARBONIC ACID

METHOD OF OBTAINING TUBOCYN BY FERMENTATION

METHOD FOR HYDROPHOBINISATION OF CHROMIC TANNED SHEEP'S SKINS FOR CLOTHING

GEL TRANSIT GLASS

SHELL- TYPE CASTING CORE AND METHOD OF ITS MANUFACTURE

WHITE THORN SORT <ORESHETZ>

INORGANIC PHOTORESIST

COMPOSITION OF PAPER

METHOD FOR MANUFACTURE OF FOIL TENSORESISTOR

LEEKS SORT "STAROSAGORSKI 72"

MANNEQUIN FOR WATER SAING

MEANS FOR OBTAINING PEARL GLOSS WITH LIQUID COSMETIC PREPARATIONS

ZUSAMMENSETZUNGEN ZUR HAARBEHANDLUNG

EPOXY- BITUMEN DYA FOR ANTICORROSIVE PREVENTION

ACID- PROOF BINDER

A METHOD OF OBTAINING ALPHA,ALPHA,ALPHA-2,4-PENTACHLORTOLUOL

TEMPORARY SUBSTITUENT FOR HUMAN SKIN

A TESTER FOR MEMORIES OF MAGNETIC DISKS

METHOD FOR PRODUCING OF MEMBRANE SEPARATORS

MEANS FOR REGULATING GROWTH AND DEVELOPMENT OF PEANUTS

ELECTROMYOGRAPHIC METHOD FOR STUDYING N. TRIGEMINUS- N. FACIALIS AND N. OCULOMOTORIUS FUNCTION

A METHOD OF OBTAINING ACTIVE CARBON FOR TECHNICAL USE

METHOD FOR OBTAINING OF 2, 2'- BIS- (P- ACETYLAMINOPHENOXY)- DIETHYLETHER

METHOD FOR PREPARING CATIONIC CARBAMIDEFORMALDEHYDE RESIN

AZODERIVATIVES OF 1, 3- DIOXYBENZENE, METHOD FOR THEIR PREPARATION AND USE THEREOF

GRAPHITIZING MODIFIER

BACTERIAL STRAIN BACILLUS BT- 271 DEGREDATING AROMATIC HYDROCARBONS

METHOD FOR MANUFACTURE OF POLE STAR FOR GENERATOR

METHOD OF CHEMICAL SENSIBILIZATION OF GELATINE ARGENTUMBROMCHLORIDE PHOTOGRAPH EMULSIONS

METHOD FOR MANUFACTURING METALLOCERAMIC CONTACTS

POLYETHER ANTIBIOTIC COMPLEX AND METHOD FOR ITS OBTAINING

METHOD OF OBTAINING OF CRYSTAL MANGANESE SULPHATE

PAPER COMPOSITION

METHOD FOR STABILIZING AND CHANGE IN TISSUE DISTRIBUTION OF SPIN MARKER NITROSOCARBAMIDE

METHOD AND MEANS FOR IMPROVING SUGAR CONTENT IN BROAD VINE OF MELNIK

ALUMINA CERAMIC MATERIAL

STRAIN ASPERGILLUS GLAUCUS 27- 1 AND ABILITY TO ACCUMULATE PROTEIN ON CELLULOSE SUBSTRATE

COMPOSITION OF BARIUM- MAGNESIUM CEMENT

OPTICAL GLASS

MEANS FOR CONTROLLING GROWTH AND DEVELOPMENT OF PEA- NUTS

METHOD FOR PREPARING GLUCOSE- 6- PHOSPHATE DEHYDROGENASE FROM BREAD BAKING YEAST

BARIUM- CALCIUM CLINKER

COMPOSITION OF PAPER FOR GOFFERING

CORN HYBRID "KNEJA 290"

COMPOSITION BASED ON POLYSTYRENE AND METHOD FOR ITS OBTAINING

GLASS FOR YELLOW LIGHT FILTER

MEANS FOR ANTISTATIC PROCESSING OF TEXTILE ARTICLES DURING CHEMICAL CLEANING

PAPER COMPOSITION

METHOD FOR OBTAINING L- 1- (3, 4, 5- TRIMETHOXY BENZYL)- 6, 7- DIHYDROXY- 1, 2, 3, 4- TETRAHYDROISOQUINOLINE- ALPHA- TARTRATE

GREIFER FUER SACKLADUNGEN

CHEMICAL COMPOUNDS

Compounds of formula (I): 2. A compound according to claim 1 , wherein A is Calkyl claim 1 , Caryl claim 1 , CarylCalkyl claim 1 , Cheteroaryl claim 1 , CheteroarylCalkyl claim 1 , CarylCalkoxy claim 1 , Chalo alkyl claim 1 , Ccycloalkyl claim 1 , CcycloalkylCalkyl claim 1 , CalkylOC(O)Calkyl claim 1 , CalkylC(O)OCalkyl claim 1 , CaryloxyCalkyl or NRRCalkyl whereby the aryl is optionally substituted with one or more substituents selected from B.3. A compound according to claim 1 , wherein A is Ccycloalkyl.4. A compound according to wherein Ris CarylCalkyl claim 1 , CarylOCalkyl claim 1 , CheteroarylCalkyl which are optionally substituted by one or more B.5. A compound according to wherein Ris phenyl or Rtogether with B form a dihydrobenzodioxinyl group.6. A compound according to wherein W is Ccycloalkyl claim 1 , Calkyl claim 1 , phenyl or pyridinyl all of optionally substituted with one or more substituents selected from halogen.7. A compound according to wherein W is phenyl substituted with fluoro.8. A compound according to wherein Ris Ris hydrogen claim 1 , Ris hydrogen claim 1 , X is O and Ris Caryl claim 1 , whereby aryl is optionally substituted by one or more B.9. A compound selected fromN-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]cyclopropanesulfonamide,N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]propane-1-sulfonamide,N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-4-yl]oxy-1-phenyl-propan-2-yl]cyclopropanesulfonamide,N-[(1R,2S)-1-[1-(6-fluoropyridin-3-yl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]cyclopropanesulfonamide,N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]methanesulfonamide,N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]-1-phenyl-methanesulfonamide,1,1,1-trifluoro-N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]methanesulfonamide,5-[(1R,2S)-2-(dimethylsulfamoylamino)-1-phenyl-propoxy]-1-(4-fluorophenyl)indazole,N-[(1R,2S)-1-[1-(4- ...

NOVEL COMPOUNDS

The present invention provides compounds of formula (I) 116-. (canceled)18. A pharmaceutically acceptable salt of the compound of claim 17 , wherein the pharmaceutically acceptable salt comprises a hydrochloride claim 17 , hydrobromide claim 17 , trifluoroacetate claim 17 , sulphate claim 17 , phosphate claim 17 , acetate claim 17 , fumarate claim 17 , maleate claim 17 , tartrate claim 17 , lactate claim 17 , citrate claim 17 , pyruvate claim 17 , succinate claim 17 , oxalate claim 17 , methanesulphonate or p-toluenesulphonate salt.19. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in and a pharmaceutically acceptable adjuvant claim 17 , diluent or carrier.20. A pharmaceutical composition as claimed in claim 19 , wherein the composition is an inhalation composition.21. A process for the preparation of a pharmaceutical composition as claimed in which comprises mixing the compound or pharmaceutically acceptable salt thereof with a pharmaceutically acceptable adjuvant claim 19 , diluent or carrier.22. A method of treating claim 17 , or reducing the risk of claim 17 , an obstructive airways disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in .23. A method as claimed in claim 22 , wherein the disease or condition is chronic obstructive pulmonary disease.24. A method as claimed in claim 22 , wherein the disease or condition is asthma.25. A method of treating allergic rhinitis which comprises administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in .26. The method as claimed in claim 22 , wherein the therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof is administered by a dry powder inhaler.27. A combination comprising a compound according to claim 17 ...

Chemical Compounds 572

Compounds of formula (I): 2. The compound according to claim 1 , wherein:{'sub': 1-6', '1-6', '1-6', '3-7', '3-7', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6', '5-10', '1-3', '5-10', '5-10', '1-4', '1-4', '1-4', '1-4', '1-4', '1-4', '1-4', '2, 'sup': 5', '6', '5', '6', '5', '6', '7', 'x, 'A is Calkyl, Chydroxyalkyl, Calkoxy, Ccycloalkyl, Cheterocycloalkyl, Chaloalkyl, CalkylOCalkyl, CalkylOCalkylOCalkyl, CalkylC(O)OCalkyl, CalkylOC(O), HOC(O), NRRCalkyl, NRRC(O), NRROC(O), RNH, CarylCalkyl, Caryl or Cheteroaryl, whereby the cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be optionally substituted by one or more substituents independently selected from halo, cyano, hydroxy, Calkyl, Calkoxy, Chaloalkyl, CalkylOC(O), CalkylOCalkyl and CalkylS(O)and Ris hydrogen, or'}{'sup': 'x', 'A forms together with Ra 5 membered azacyclic ring optionally having one or more further heteroatoms independently selected from O and N;'}{'sup': 1', '1a', '1', '1a, 'sub': 1-4', '1-4', '1-4', '1-4', '1-4, 'Rand Rare independently selected from hydrogen, Calkyl, Chydroxyalkyl, CalkylOCalkyl and Chaloalkyl, or Rand Rtogether are oxo;'}{'sup': '2', 'sub': '1-4', 'Ris hydrogen or Calkyl;'}{'sup': '2', 'Ris hydrogen;'}{'sup': '3', 'sub': 5-10', '5-10', '1-4', '5-10', '5-10', '1-4', '5-10, 'Ris Caryl, CarylCalkyl, CarylO, CarylOCalkyl or Cheteroaryl, which may be optionally substituted by one or more substituents independently selected from B;'}{'sub': 1-4', '1-4', '1-4', '1-4', '1-4', '3-6', '1-3', 'n', '1-4', '1-3', 'n', '1-4, 'B is hydroxy, Calkyl, Calkoxy, CalkylCthioalkyl, Cthioalkyl, CcycloalkylS, CalkylS(O)Calkyl, CalkylS(O), Chaloalkyl or halo;'}n is 1 or 2;{'sup': '4', 'Ris hydrogen;'}{'sub': 1-4', '3-7', '1-3', '3-6', '1-4', '1-4', '1-4, 'sup': 10', '11, 'W is phenyl, Calkyl, Ccycloalkyl, pyridinyl, pyridazinyl or pyrimidinyl all of which are optionally substituted by one or more substituents independently selected from Chydroxyalkyl, CheterocycloalkylCalkyl ...

PERSONAL CARE COMPOSITION

A multi-phase personal care composition comprising at least two visually distinct phases in physical contact with one another characterised in that at least one phase comprises polyacrylate-1 crosspolymer and one phase is a conditioning gel phase. 1. A multi-phase personal care composition comprising at least two visually distinct phases in physical contact with one another characterised in that at least one phase comprises polyacrylate-1 crosspolymer and one phase is a lamellar conditioning phase.2. A multi-phase personal care composition according to in which the lamellar conditioning phase comprises a cationic conditioning ingredient.3. A multi-phase personal care composition according to in which at least one phase is visually clear.4. A multi-phase personal care composition according to in which at least one phase is opaque.5. A multi-phase personal care composition according to in which at least one phase comprises electrolyte.6. A multi-phase composition according to in which the electrolyte and polyacrylate-1 crosspolymer are in the same phase.7. A multi-phase personal care composition according to in which each phase comprising polyacrylate crosspolymer further comprises glycolic acid.8. A multi-phase personal care composition according to in which the ratio of polyacrylate crosspolymer to glycolic acid is from 3:1 to 1:1.9. A multi-phase personal care composition according to in which each phase comprising polyacrylate-1 crosspolymer further comprises water and in which the weight ratio of water to polyacrylate-1 crosspolymer is from 6:1 to 5:1.10. A multi-phase personal care composition according to for use on hair.11. A personal care composition according to in which the differing phases of the composition are co-extruded.12. A pack comprising a multi-phase composition as claimed in . The present invention relates to multi-phase personal care compositions, more particularly hair care compositions.Hair care compositions that have more than one phase are ...

HAIR CONDITIONING COMPOSITION

A hair conditioning composition comprising an oil blend, said blend comprising: (i) from 10% to 95%, by weight based on total weight, of a first oily component which is selected from coconut oil, sunflower oil, almond oil and mixtures thereof, and (ii) from 5% to 90%, by weight based on total weight, of a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20 carbon atoms. 1. A rinse-off hair conditioning composition comprising a cationic surfactant and an oil blend , said blend comprising:(i) from 10% to 95%, by weight based on total weight, of a first oily component which is selected from coconut oil, sunflower oil, almond oil and mixtures thereof, and(ii) from 5% to 90%, by weight based on total weight, of a second oily component which is one or more hydrocarbon oils of average carbon chain length less than 20 carbon atoms,wherein, the oil blend is present in the composition at from 0.1 to 2% wt.2. Composition according to claim 1 , in which the total content of the first oily component ranges from 20% to 80% by weight based on total weight of the oil blend.3. Composition according to claim 1 , in which the hydrocarbon oil is light mineral oil.4. Composition according to claim 1 , in which the total content of hydrocarbon oil ranges from 20% to 80% by weight based on total weight of the oil blend.5. Composition according to claim 1 , in which the first oily component: hydrocarbon oil weight ratio ranges from 90:10 to 10:90 and most preferably from 80:20 to 20:80. The present invention relates to a hair conditioning composition comprising an oil blend.WO 01/95866 (Unilever) discloses a hair oil comprising mineral oil and coconut oil. This disclosure demonstrates that adding mineral oil to coconut oil reduces greasiness and increases penetration of total oil in hair.J. Cosmetic Sci., 56, 283-295 (September/October 2005) discloses that oils applied on hair leave an oily film and oil makes capillary bridges between ...

Novel Amide Compounds

The present invention provides compounds of formula (1) 110-. (canceled)11. A compound , wherein the compound is:(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Cyanomethyl)sulfanyl]carbonyl}-11-hydroxy-7-{3-[(2-methoxyethyl)carbamoyl]phenyl}-10a,12a-dimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl propanoate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-7-{3-[(2-methoxyethyl)carbamoyl]phenyl}-10a,12a-dimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl propanoate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-7-{3-[(2-methoxyethyl)carbamoyl]phenyl}-10a,12a-dimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl methoxyacetate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Cyanomethyl)sulfanyl]carbonyl}-11-hydroxy-7-{3-[(2-methoxyethyl)carbamoyl]phenyl}-10a,12a-dimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl cyclopropanecarboxylate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-7-{3-[(2-methoxyethyl)carbamoyl]phenyl}-10a,12a-dimethyl-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl cyclopropanecarboxylate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Cyanomethyl)sulfanyl]carbonyl}-11-hydroxy-10a,12a-dimethyl-7-(3-{[2-(methylsulfanyl)ethyl]carbamoyl}phenyl)-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl propanoate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-10a,12a-dimethyl-7-(3-{[2-(methylsulfanyl)ethyl]carbamoyl}phenyl)-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl propanoate,(1R,3aS,3bS,10aR,10bS,11S,12aS)-1-{[(Fluoromethyl)sulfanyl]carbonyl}-11-hydroxy-10a,12a-dimethyl-7-(3-{[2-(methylsulfanyl)ethyl]carbamoyl} ...

Low-profile optical arrangement

The present invention relates to an optical arrangement ( 1 ) having an optical axis (X) and comprising a base member ( 70 ), a cup shaped reflector ( 10 ) having an inner surface ( 12 ) facing towards the optical axis, at least one solid state light source ( 40, 42 ) arranged at the optical axis on the base member, and a lens comprising a center lens portion ( 20 ) and an annular lens portion ( 30 ), and arranged in front of the at least one solid state light source in a light exit direction. The center lens portion has a dome shaped outer surface ( 22 ) and the annular lens portion has an outer surface ( 32 ) with a convex shape facing the inner surface of the reflector. The reflector and the lens are formed together as one solid piece of material.

Estimating camera pose

A system for estimating a current camera pose corresponding to a current point in time using a previous camera pose corresponding to a previous point in time, of a camera configured to generate a sequence of image frames. The system performs operations, including: generating, using one or more neural networks, a neural network pose prediction for the current image frame; and adjusting a previous camera pose using inertial measurement unit data representing a motion of the camera between the previous point in time and the current point in time, to provide an inertial measurement unit pose prediction for the current point in time. The inertial measurement unit pose prediction, and the neural network pose prediction are combined in order to estimate the current camera pose.

HAIR TREATMENT COMPOSITIONS

A method of protecting the internal protein of hair from damage, comprising the step of applying, to the hair, a hair treatment composition comprising a lactone, a disaccharide, an inorganic salt and an organic acid or salt thereof, having a pH in the range of from 3 to 6.5, prior to the application of a damage insult to the hair, and a use of such a hair treatment composition, in the treatment of hair, to protect hair from damage. 1. A method of protecting hair from damage , comprising the step of applying , to the hair multiple times , a hair treatment composition comprising a lactone , a disaccharide , an inorganic salt and an organic acid or salt thereof , having a pH in the range of from 3 to 6.5 , prior to the application of a damage insult to the hair.2. The method of claim 1 , wherein the step of applying is performed from 2 to 50 times.3. The method of claim 1 , wherein the cause of the damage is selected from mechanical means claim 1 , chemical means and environmental means.4. The method of claim 3 , wherein the damage is selected from lightening claim 3 , chemical straightening claim 3 , colouring claim 3 , heat styling claim 3 , and mixtures thereof.5. The method of claim 3 , wherein the damage is caused by bleaching.6. The method of claim 1 , wherein the hair treatment composition is a rinse off hair treatment composition.7. The method of claim 6 , in which the shampoo and the conditioner are used sequentially.8. The method of claim 1 , wherein the lactone is a delta lactone selected from gluconolactone claim 1 , galactonolactone claim 1 , glucuronolactone claim 1 , galacturonolactone claim 1 , gulonolactone claim 1 , ribonolactone claim 1 , saccharic acid lactone claim 1 , pantoyllactone claim 1 , glucoheptonolactone claim 1 , mannonolactone claim 1 , galactoheptonolactone and mixtures thereof9. The method of claim 8 , wherein the lactone is gluconolactone.10. The method of claim 1 , wherein the disaccharide comprises of pentose or hexose sugars.11. ...

Device and method for analysis of milk

This device and method can be used for monitoring and control of the milk quality, monitoring and control of the health of dairy animal and herd management and decision-making. The device for milk analysis is composed of tanks for water and reagent, a milk probe, a unit for analysis and management and a unit for transfer and monitoring with software applications. The samples are mixed in a mixing flask, previously subjected to an ultrasonic and temperature measurement as well as a measurement of conductivity. The movement of the fluid through the system is performed by peristaltic pumps. The actual measurement takes place at the outflow of the measured sample in one of two funnels with elongated ends with integrated capillary of the ends of each. To the funnels are mounted a pair of motion sensors.

Methods and systems for eliminating and reducing attack surfaces through evaluating reconfigurations

A method of performing a security assessment of a system includes analyzing a static structure of the system; storing, in a semantic system model, structure information about the static structure of the system; observing the system during a plurality of discrete temporal system states; storing, in the semantic system model, dynamic information about the system during the plurality of discrete temporal system states; performing a semantic composition analysis on the structure information to identify at least one vulnerability of the system; performing a flow analysis on the dynamic information to identify at least one anomalous behavior of the system during at least one of the plurality of discrete temporal system states; and generating, based on the at least one vulnerability of the system and the at least one anomalous behavior of the system, a vulnerability assessment of the system.

Collet chuck

Auqeous solution for vibroabrasive deburring

High-power microscope planapochromatic lens

Crane boom support articles

Trencher

Stationary offshore platform

Method of oil anti-corrosive property determination

Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors

Scraper with screw loader

Pin delay system for microwave devices of m-type

Novel compounds

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, t, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Method of making multicolour transfer images

DEHYDRATION OF METHANOL TO DIMETHYL ETHER EMPLOYING CATALYSTS BASED ON ZEOLITHE SUPPORTED ON SILICON CARBIDE

Preparation of dimethyl ether by catalytic dehydration of methanol using zeolite immobilized on a silicon carbide support as a catalyst, is claimed.

Preparing dimethyl ether by catalytic dehydration of methanol using zeolite immobilized on a silicon carbide support, useful as a precursor for synthesis of various compounds e.g. low molecular weight olefins and as gas propellant

Preparation of dimethyl ether by catalytic dehydration of methanol using zeolite immobilized on a silicon carbide support as a catalyst, is claimed.

Torque teno virus (ttv) isolates and compositions

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus ("TTV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

16 alpha, 17 alpha-acetal glucocorticosteroidal derivatives and their use

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Torque teno virus (TTV) isolates and compositions

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus ("TTV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

Novel compounds

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, t, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Ceramic material from aluminium titanite and method for its preparing

The ceramic material finds applications in engine production, electronics and other industrial branches, particularly in the manufacture of thermostable, mechanically resistant and electrically insulating parts. It can be synthesized by the sol-gel method at temperatures below 1500 degrees C and has a low coefficient of thermal expansion and high mechanical strength. The ceramic material contains 56.1 wt.% of aluminium oxide and 43.9 wt.% of titanium oxide, appearing as titanium ethylate and aluminium butylate, and in excess of 100 % of the following zirconium propylate additives, expressed in wt.%: 1-10 and, if necessary, up to 10 boric ethylate, up to 6 zinc fluoride and 0.1-10 tetraethylorthosilicate. This ceramic material is prepared using the sol-gel process in two stages by carrying out hydrolysis and thermal treatment of metallo-organic compounds.

Preparing composite, useful e.g. as catalyst in liquid/gaseous phase reactions, comprises incorporating catalyst e.g. in porous silicon carbide substrate, growing nanotubes/carbon nanofibers, and transforming nanotubes/nanofibers

Preparing composite comprising nanofibers or nanotubes on a porous silicon carbide substrate, comprises: incorporating a catalyst for growth of nanotubes or nanofibers, in porous silicon carbide substrate, or in silicon carbide precursor; growing nanotubes or carbon nanofibers from a mixture comprising a hydrocarbon and hydrogen; and optionally transforming the nanotubes or carbon nanofibers into silicon carbide nanofibers. An independent claim is included for a composite comprising porous silicon carbide substrate with carbon nanotubes or nanofibers and/or silicon carbide nanofibers, preferably a foamy substrate of beta -silicon carbide with a specific surface of at least 10 m 2>/ g with silicon carbide nanofibers.

Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity

Novel compounds

ESTER OR IMIDAZOLYL AMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR

SE REFIERE A DERIVADOS ESTER O AMIDA DE IMIDAZOLILO DE FORMULA (I), EN DONDE A ES ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), ALCOXI(C1-C6), HETEROCICLOALQUILO(C3-C7), ENTRE OTROS; Rx ES H; O A JUNTO CON Rx FORMAN UN HETEROCICLO; R1 Y R1a SON INDEPENDIENTEMENTE UN ENLACE, H, OXI, ENTRE OTROS; R2 ES H; R3 ES ARILO(C5-C10), ARILO(C5-C10)ALQUILO(C1-C4), ENTRE OTROS R4 ES H; W ES FENILO, ALQUILO(C1-C4), ENTRE OTROS; X ES O, S, ENTRE OTROS; Y ES H, HALO, ALQUILO(C1-C4); Z ES O U S. SON SELECCIONADOS: N-[(1R,2S)-1-[1-(4-FLUOROFENIL)INDAZOL-5-IL]OXI-1-FENIL-PROPAN-2-IL]CICLOPROPANOCARBOXAMIDA, N-[(1R,2S)-1-(4-ETILFENIL)-1-[1-(4-FLUOROFENIL)INDAZOL-5-IL]OXIPROPAN-2-IL]2-HIDROXI-ACETAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON NO ESTEROIDEOS QUE ACTUAN COMO MODULADORES DEL RECEPTOR DE GLUCOCORTICOIDES, SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ASMA, COPD, ENTRE OTROS REFERS TO IMIDAZOLYL ESTER OR AMIDE DERIVATIVES OF FORMULA (I), WHERE A IS ALKYL (C1-C6), HYDROXIALKYL (C1-C6), ALCOXY (C1-C6), HETEROCICLOALKYL (C3-C7), AMONG OTHERS; Rx IS H; OR TOGETHER WITH Rx FORM A HETEROCYCLE; R1 AND R1a ARE INDEPENDENTLY A LINK, H, OXI, AMONG OTHERS; R2 IS H; R3 IS ARYL (C5-C10), ARYL (C5-C10) ALKYL (C1-C4), AMONG OTHERS R4 IS H; W IS PHENYL, ALKYL (C1-C4), AMONG OTHERS; X IS O, S, AMONG OTHERS; Y IS H, HALO, (C1-C4) ALKYL; Z IS OU S. THEY ARE SELECTED: N - [(1R, 2S) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXI-1-PHENYL-PROPAN-2-IL] CYCLOPROPANOCARBOXAMIDE, N- [ (1R, 2S) -1- (4-ETHYLPHENYL) -1- [1- (4-FLUOROPHENIL) INDAZOL-5-IL] OXIPROPAN-2-IL] 2-HYDROXY-ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THESE COMPOUNDS ARE NON-STEROIDES THAT ACT AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR, BEING USEFUL IN THE TREATMENT OF INFLAMMATORY DISORDERS SUCH AS ASTHMA, COPD, AMONG OTHERS

Laminated lithium-sulfphur cell

A lithium-sulphur electrochemical cell comprising a laminate comprising: a lithium anode comprising a layer of lithium metal foil or lithium metal alloy foil; a cathode comprising an active sulphur material; a porous separator disposed between the lithium anode and the cathode;and an electrolyte; wherein: the laminate is folded in a zigzag configuration; and the cathode is offset relative to the lithium anode in the laminate, such that the cathode is accessible from one side of the laminate and the lithium anode is accessible from an opposite side of the laminate.

GURINCHUK 11) V A

Salts of n-(vinyloxiethyl)dithiocarbamic acid, method of obtaining thereof and pesticides based on them

Salts of N-(vinyloxiethyl)dithiocarbamic acid have the following formula: [CH2=CHOCH2CH2NHC(S)S]nM, where M is K, Na, Zn, Cu; n is equal to 1.2. Potassium and sodium salts of N-(vinyloxiethyl)dithiocarbamic acid are obtained by reaction of vinyloxiethylamine, carbon disulphide and hydroxide of potassium or sodium in water or in the medium of organic solvents. Zinc and copper salts of N-(vinyloxiethyl)dithiocarbamic acid are obtained from the above mentioned potassium or sodium salts of N-(vinyloxiethyl)dithiocarbamic acid by treating them with water-soluble salts of zinc and copper in the water medium. Said salts are pesticides having a wide range of action and possess fungicidal, bactericidal acaricidal and insecticidal activity.

Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity

Composite consisting of nanotubes or nanofibres on a β-sic film

L'invention concerne un procédé de fabrication d'un composite comportant des nanofïbres ou nanotubes sur un substrat poreux de β-SiC, ledit procédé comportant les étapes suivantes : (a) On incorpore dans ledit substrat poreux de β-SiC, ou dans un précurseur de SiC, un catalyseur de croissance de nanotubes ou nanofibres; (b) On fait croître des nanotubes ou nanofibres de carbone à partir d'un mélange comprenant au moins un hydrocarbure et de l'hydrogène; (c) Optionnellement, on transforme lesdits nanotubes ou nanofibres en carbone en nanofibres de SiC. Ce produit composite peut être utilisé comme catalyseur ou support de catalyseur.

ulcer agent

Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity

Compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.

Laminated lithium-sulphur cell

Interactive System and Method of Use

An interactive system and a method of use for treatment and training a person with ASD or a similar condition or problem including primary part of holograms and holographic assistant, and secondary part of a group of drones and a robot that involves the use of a pair of holograms that imitate and demonstrate the functions of the right hemisphere of the brain and the left hemisphere of the brain, the exchange of information between them through the communication between the two. The interactive system can be used in training humanoid robots.

Inducible alphaviral/orip based gene expression system

The present invention relates to compositions and methods that allow the production of polypeptides and untranslated RNA molecules in host cells. More specifically, the invention provides nucleic acid molecules, expression systems, recombinant host cells, methods and kits, which enable the production and/or isolation and/or purification of polypeptides and untranslated RNA molecules. The compositions and methods of the invention can be applied in a regulatable expression system that is transiently transfected into mammalian host cells.

Scraper bucket with scooping grip

compound pharmaceutically acceptable salt, tautomer, isomer or stereoisomer thereof, pharmaceutical composition and process for the synthesis of said compound

COMPOSTO, SAL FARMACEUTICAMENTE ACEITÁVEL, TAUTÔMERO, ISÔMERO, ESTEREOISÔMERO DO MESMO, COMPOSIÇÃO FARMACÊUTICA, PROCESSO PARA A SÍNTESE DO COMPOSTOE USO DO COMPOSTO. A presente invenção se refere a compostos que são inibidores de vírus da hepatite B (HBV). Compostos desta invenção são úteis sozinhos ou em combinação com outros agentes para tratar, melhorar, prevenir ou curar infecção HBV e condições relacionadas. A presente invenção também se refere a composições farmacêuticas contendo os ditos compostos. COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT, TAUTOMER, ISON, STEREOISOMER OF THE SAME, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE SYNTHESIS OF THE COMPOUND AND USE OF THE COMPOUND. The present invention relates to compounds which are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents to treat, ameliorate, prevent or cure HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity

The present invention provides compounds of formula (I) wherein n, R1, R2, X1, X2, X3, X4' X5, R3a, R3b, R4, R5 and R6 are defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Chemical compounds 572

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

Laminated lithium-sulphur cell

A lithium-sulphur electrochemical cell comprising a laminate comprising: a lithium anode comprising a layer of lithium metal foil or lithium metal alloy foil; a cathode comprising an active sulphur material; a porous separator disposed between the lithium anode and the cathode; and an electrolyte; wherein: the laminate is folded in a zigzag configuration; and the cathode is offset relative to the lithium anode in the laminate, such that the cathode is accessible from one side of the laminate and the lithium anode is accessible from an opposite side of the laminate.

Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity

The invention provides compounds of formula (I) wherein m, R 1 , n, R 2 , q, p, X, Y, R 3 , R 4 , t and, R 5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Novel combinations

The invention provides a pharmaceutical product comprising, in combination, (1) a named glucocorticosteroid receptor agonist and (2) a ß2 adrenoreceptor agonist, a dual ß2 adrenoreceptor agonist/M3 receptor antagonist, a muscarinic antagonist, a p38 kinase inhibitor, a neutrophil elastase inhibitor, a phosphodiesterase PDE4 inhibitor, an IKK2 kinase inhibitor or a non-steroidal glucocorticoid receptor agonist, and the use of said product in treating respiratory diseases.

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus ("PEDV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.

Microwave resonator for non-sinusoidal periodic waveform

Chemokine receptor modulators

Provided is a compound of Formula (I) with the different optional substituents as given in the claims. Further provided is the use of the composition in the manufacture of a medicament for use in the treatment of inflammatory or airways disease.

Improved assays for potency of human retinal pigment epithelium (RPE) cells and photoreceptor progenitors

This disclosure provides a new phagocytosis assay to test the function of RPE cells and photoreceptor progenitors using a pH sensitive fluorescent label.

Method of producing flour half-finished product for pancakes with filling

Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders.

La presente invención se relaciona con nuevos derivados éster o amida de indazolilo, composiciones farmacéuticas que comprenden los derivados, procesos para preparar los nuevos derivados y el uso de los derivados como medicamento (por ejemplo en el tratamiento de un estado de enfermedad inflamatoria).

Cement-manufacturing plant and process for producing cement clinker

Hair treatment compositions

A method of protecting the internal protein of hair from damage, comprising the step of applying, to the hair, a hair treatment composition comprising a lactone, a disaccharide, an inorganic salt and an organic acid or salt thereof, having a pH in the range of from 3 to 6.5, prior to the application of a damage insult to the hair, and a use of such a hair treatment composition, in the treatment of hair, to protect hair from damage.

Method for preparing of replaced 4- (1- methyl- 4- pyridile)- 4h- benzo |4, 5] cyclohepta |1, 2- b] thiophen- 4- ols

Increased yield rates and high purity of the compounds with re-producible results can be achieved by this method. Substituted 4-1/1-methyl-4-piperidil/-4H-benzo /4,5/ cyclohepta /1,2-b/ thiophen-4-ols with the following formula:<IMAGE>in which A is H or OCH3, are prepared by reacting an organo-magnesium compound with 4H-benzo-/4,5/ cyclohepta /1,2-b/ thiophen-4-one with the following formula:<IMAGE>in which the values of H are as indicated. The organo-magnesium compound is obtained by adding drop-wise, while boiling, a mixture of 1-methyl-4-chloromethylpiperadine, 1,2-dibromethane and tetrahydrofuran to magnesium in tetrahydrofuran at molar ratios of 1 : 1.1 : 0.05 : 0.1 : 4. The obtained organo-magnesium halide reacts with 4H-benzo-/4,5/ cyclohepta /1,2-b/ thiophen-4-one at a molar ratio of 1 : 0.7, while isolating the final product out of the reaction mixture after hydrolysis is carried out directly by crystallization.

Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity

The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

New tricyclic spirropiperidine or spiropyrrolidine

Torque teno virus (TTV) isolates and compositions

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use

The present invention provides compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Antiulcer means

Novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity

The present invention provides compounds of formula (I) wherein n, R 1 , R 2 , X 1 , X 2 , X 3 , X 4, X 5 , R 3a , R 3b , R 4 , R 5 and R 6 are defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Method for preparing of zirconium ceramic pigments

These pigments are used in ceramic technology as colouring agents for ceramic masses, glazes, glass and similar. They are synthesised using sol-gel technology at reduced temperatures. The bulk of zirconium phase is synthesised over the temperature range 800 - 1100 degrees C. This enhances the intensity and purity of the colour. The pigment preparation method is based on adding 60-65.5 % by mass (expressed as zirconium oxide) of zirconium nitrate solution and a solution of one of the salts carrying the chromoform ions - iron chloride hexahydrate, manganese chloride hexahydrate, ammonium chromate, cobaltous nitrate hexahydrate, ammonium metavanadate or nickel chloride hexahydrate - in quantities ranging between 5.2 - 7.0 % by mass, expressed as their respective oxides, to the silica sol.

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

SALTS OF N- (VINYLOXYETHYL) DITIOCARBAMIC ACID, PROCESS FOR THE PREPARATION OF THE SAME, AND PESTICIDE

Scraper

Steroidal [3,2-c]pyrazole compounds,with glucocorticoid activity

Augmented reality system

An AR system is provided, the AR system including one or more sensors, storage, one or more communications modules, and one or more processors. The one or more sensors generate sensed data representing at least part of an environment in which the AR system is located. The one or more communications modules transmit localization data to be used in determining the location and orientation of the AR system. The one or more processors are arranged to obtain sensed data representing an environment in which the AR system is located, process the sensed data to identify a first portion of the sensed data which represents redundant information, derive localization data, wherein the localization data is derived from the sensed data and the first portion is obscured during the derivation of the localization data, and transmit at least a portion of the localization data using the one or more communication modules.

Compounds and compositions for treating tissue ischemia

There is disclosed a genus of compounds and pharmaceutical compositions that are protective for mitigating damage associated with tissue ischemia, particularly stroke (CNS ischemia), and ischemia of the myocardium. The present invention further provides a method for treating tissue damage cause d by ischemia. Lastly, the present invention provides a method for treating tissue damage caused by providing a compound that inhibits the cytotoxic activity of 3-aminopropanal.

Idometric method for copper (iii) and the amount of copper (iii) and copper (ii) in superconductive ceramic materials on copper oxides basic determination

The method is applicable for analysis of copper (III) and copper (II) in ceramic materials, containing either of the copper valent variations, especially in superconductive ceramic materials, containing the oxides of yttrium (lanthanide), barium (strontium), and copper. It highly accurate and reproducible in determination of copper (III), where copper (III) and the sum of copper (III), and copper (II) are determined from the same sample. According to the method, the test sample is dissolved in 1M hydrochloric acid in inert atmosphere in the presence of potassium iodide and as a result, copper (III) and copper (II) in the sample are reduced to copper (I) which is precipitated as copper (I) iodide, where iodine is released. After that, argon-blown solutions of 0.1M EDTA and 2.5M sodium acetic buffer with pH of 4.8-4.9 are added to the sample. As a result, copper (I) is oxidized with a portion of the iodine to copper (II) and is combined in a complex with EDTA. The remaining quantity of iodine, equivalent only to the content of copper (III), is titrated with a standard solution of sodium thiosulphate, using starch as an indicator. Then, potassium iodide and 4M sulphuric acid are added to the solution in order to break the copper (II) - EDTA compound and to reduce copper (II) to copper (I), which causes release of iodine in a quantity, equivalent to the sum of copper (III) and copper (II). The released quantity of iodine is titrated with a standard solution of sodium thiosulphate, using starch as an indicator.

Hair treatment compositions

A hair treatment composition, comprising a non-emulsified silicone pressure sensitive adhesive dissolved in a volatile solvent.

Inhibitors of hepatitis b virus

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing the compounds.

COMPOUNDS OF [3,2-C] PIRAZOL STEROIDS WITH GLUCOCORTICOID ACTIVITY

La presente invencion proporciona compuestos de formula (I) en donde n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 y R6 son tal como se definen en la memoria descriptiva, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en terapia.

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

The present invention is directed to novel nucleotide and amino acid sequences of Porcine Epidemic Diarrhea Virus ("PEDV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine PEDV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length PEDV genomes that can replicate efficiently in host animals and tissue culture.

Infectious clones of torque teno virus

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus ("TTV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

Laminated lithium-sulfphur cell

A lithium-sulphur electrochemical cell comprising a laminate comprising: a lithium anode comprising a layer of lithium metal foil or lithium metal alloy foil; a cathode comprising an active sulphur material; a porous separator disposed between the lithium anode and the cathode;and an electrolyte; wherein: the laminate is folded in a zigzag configuration; and the cathode is offset relative to the lithium anode in the laminate, such that the cathode is accessible from one side of the laminate and the lithium anode is accessible from an opposite side of the laminate.

Human monoclonal antibodies against human chemokine receptor ccr6

Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR6 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR6 receptor, including cancers, inflammatory diseases and fibrotic diseases. Other uses include detection of human CCR6 receptor in biological samples for diagnostic or evaluative purposes.

Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders

Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity

Disclosed are steroidal [3,2-C] pyrazole compounds of formula (I) or a pharmaceutically acceptable salt thereof, with glucocorticosteroid receptor agonist activity, processes for their preparation and their use in treating asthma, chronic obstructive pulmonary disease and allergic rhinitis.

Chemical compounds 572

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments.

16-alpha and 17-alpha derivatives of glucocorticosteroids and their uses

derivados 16-alfa e 17-alfa de glicocorticosteroides e seus usos a presente invenção provê compostos da fórmula(l) em que r1 r2 r3 r4 r5 e r6 são conforme definidos no relatório, um processo para o seu preparo, composições farmacêuticas contendo-os e o seu uso em terapia. 16-alpha and 17-alpha derivatives of glucocorticosteroids and their uses The present invention provides compounds of formula (I) wherein r1 r2 r3 r4 r5 and r6 are as defined in the report, a process for their preparation, pharmaceutical compositions containing them. and its use in therapy.

Assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors

This disclosure provides a new phagocytosis assay to test the function of RPE cells and photoreceptor progenitors using a pH sensitive fluorescent label.

Novel compounds 243

Augmented reality system

An AR system is provided, the AR system including one or more sensors, storage, one or more communications modules, and one or more processors. The one or more sensors generate sensed data representing at least part of an environment in which the AR system is located. The one or more communications modules transmit localization data to be used in determining the location and orientation of the AR system. The one or more processors are arranged to obtain sensed data representing an environment in which the AR system is located, process the sensed data to identify a first portion of the sensed data which represents redundant information, derive localization data, wherein the localization data is derived from the sensed data and the first portion is obscured during the derivation of the localization data, and transmit at least a portion of the localization data using the one or more communication modules.

Ripper for firm ground

Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors

HAIR TREATMENT COMPOSITIONS.

Un procedimiento de fabricación de una composición de tratamiento capilar que comprende las etapas de i) preparar una emulsión de adhesivo sensible a la presión de silicona en la que el adhesivo sensible a la presión de silicona comprende un fluido de silicona y un silicato, y la emulsión comprende un tensioactivo y una fase disolvente de hidrocarburo dispersa en una fase acuosa continua; e ii) añadir la emulsión de adhesivo sensible a la presión a una composición de base.

Hair treatment compositions

Infectious clones of Torque teno virus

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus ("TTV"), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

COMPOSITIONS FOR HAIR TREATMENT

Un método para proteger del daño a la proteína interna del cabello que comprende el paso de aplicar sobre el cabello, una composición para el tratamiento del cabello que comprende una lactona, un disacárido, una sal inorgánica y una sal orgánica o su sal, con un pH que varia entre 3 y 6,5, antes de la aplicación de una agresión sobre el cabello, y un uso de una composición como esta para el tratamiento del cabello, en el tratamiento del cabello, con el fin de proteger del daño al cabello. A method for protecting from damage to the internal hair protein comprising the step of applying on the hair, a hair treatment composition comprising a lactone, a disaccharide, an inorganic salt and an organic salt or its salt, with a pH that varies between 3 and 6.5, before the application of an aggression on the hair, and a use of a composition like this for the treatment of hair, in the treatment of hair, in order to protect from damage to hair .

Benzimidazol derivatives modulate chemokine receptors

The invention provides compounds of general formula (I) wherein A, X, m, R 1 , N, R 2 , Z 1 , Z 2 , Q, R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , t and R 16 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Novel compounds

Use of a nutritional composition for treating hypertension

The present invention relates to the use of a nutritional composition containing green tea extract for the preparation of a pharmaceutical composition for inhibiting smooth muscle cell contraction, and hence lowering hypertension.

Novel tricyclic spiropiperidine compounds, their syntheses and their applications as modulators of chemokine receptor activity

Forbindelser med formel (I), hvori R1, R3, R4, R5, R6, R7 og R10 er som definert i beskrivelsen, er beskrevet. Foreliggende oppfinnelse angår også farmasøytisk sammensetning som innbefatter nevnte forbindelser og anvendelsen av nevnte forbindelser ved behandling. Foreliggende oppfinnelse angår videre fremgangsmåter for fremstilling av nevnte forbindelser og nye intermediater anvendelige ved fremstilling derav. I tillegg angår oppfinnelsen salter og polymorfe former av de nye forbindelsene, så vel som fremstillingen derav.

Arrangement and method for recording signals of biological origin

The invention relates to the multi-channel recording of signals of various biological origins in the frequency range of 0 to several kilohertz, preparation of the reference potential for the differential amplifier on each channel, from the determined data from the analogue to digital converter and predominantly, though not exclusively, all areas of medicine in which biosignals are used.

Cyclic inhibitors of hepatitis b virus

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.